Faculty Profile
Dr. Amir Faisal
Associate Professor
Department Of Biology
Dr. Amir Faisal received his PhD in Cell Biology from Friedrich Miescher Institute for Biomedical Research/University of Basel, Switzerland in 2004. During his PhD he identified novel roles for Shc protein, an important adaptor downstream of tyrosine kinases, in insulin signalling and cytoskeletal reorganization. He received his first postdoctoral training (2004-2008) in Protein Phosphorylation Laboratory at London Research Institute where he discovered that another adaptor protein, MyD88, couples Protein Kinase C epsilon to Toll like receptors during innate immunity. From 2008 to 2014, he worked at Cancer Therapeutics Unit of Institute of Cancer Research in Sutton first as postdoctoral fellow and later as senior scientist. He played an important role in progression of several drug discovery projects, one of which resulted in discovery of a pre-clinical development candidate that will undergo phase I clinical trials in 2016. After joining LUMS in August 2014, he has been establishing a cancer therapeutics lab at SBASSE.
| Title | Publication | Author | Year |
|---|---|---|---|
| Synthesis and evaluation of novel ??-substituted chalcones with potent anti-cancer activities and ability to overcome multidrug resistance | Bioorganic Chemistry | Riaz S., Iqbal M., Ullah R., Zahra R., Chotana G.A., Faisal A., Saleem R.S.Z. | 2019 |
| Identification and characterization of SSE15206, a microtubule depolymerizing agent that overcomes multidrug resistance | Scientific Reports | Manzoor S., Bilal A., Khan S., Ullah R., Iftikhar S., Emwas A.-H., Alazmi M., Gao X., Jawaid A., Saleem R.S.Z., Faisal A. | 2018 |
| ATLANTIS - Attractor Landscape Analysis Toolbox for Cell Fate Discovery and Reprogramming | Scientific Reports | Shah O.S., Chaudhary M.F.A., Awan H.A., Fatima F., Arshad Z., Amina B., Ahmed M., Hameed H., Furqan M., Khalid S., Faisal A., Chaudhary S.U. | 2018 |
| Introduction of a Methyl Group Curbs Metabolism of Pyrido[3,4- d]pyrimidine Monopolar Spindle 1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical Candidate N 2 -(2-Ethoxy-4-(4-methyl-4 H-1,2,4-triazol-3-yl)phenyl)-6-methyl- N 8 -neopentylpyrido[3,4- d]pyrimidine-2,8-diamine (BOS172722) | Journal of Medicinal Chemistry | Woodward H.L., Innocenti P., Cheung K.-M.J., Hayes A., Roberts J., Henley A.T., Faisal A., Mak G.W.-Y., Box G., Westwood I.M., Cronin N., Carter M., Valenti M., De Haven Brandon A., O'Fee L., Saville H., Schmitt J., Burke R., Broccatelli F., Van Montfort R.L.M., Raynaud F.I., Eccles S.A., Linardopoulos S., Blagg J., Hoelder S. | 2018 |
| CDK1 inhibition facilitates formation of syncytiotrophoblasts and expression of human Chorionic Gonadotropin | Placenta | Ullah R., Dar S., Ahmad T., de Renty C., Usman M., DePamphilis M.L., Faisal A., Shahzad-ul-Hussan S., Ullah Z. | 2018 |
| Aurora B prevents premature removal of spindle assembly checkpoint proteins from the kinetochore: A key role for Aurora B in mitosis | Oncotarget | Gurden M.D., Anderhub S.J., Faisal A., Linardopoulos S. | 2018 |
| Nicotine exposure augments renal toxicity of 5-azacytidine through p66shc: Prevention by resveratrol | Anticancer Research | Arany I., Hall S., Faisal A., Dixit M. | 2017 |
| Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy | British Journal of Cancer | Faisal A., Mak G.W.Y., Gurden M.D., Xavier C.P.R., Anderhub S.J., Innocenti P., Westwood I.M., Naud S., Hayes A., Box G., Valenti M.R., De Haven Brandon A.K., O'Fee L., Schmitt J., Woodward H.L., Burke R., Vanmontfort R.L.M., Blagg J., Raynaud F.I., Eccles S.A., Hoelder S., Linardopoulos S. | 2017 |
| Natural products from Cuscuta reflexa Roxb. with antiproliferation activities in HCT116 colorectal cell lines | Natural Product Research | Riaz M., Bilal A., Ali M.S., Fatima I., Faisal A., Sherkheli M.A., Asghar A. | 2017 |
| Synthesis and evaluation of modified chalcone based p53 stabilizing agents | Bioorganic and Medicinal Chemistry Letters | Iftikhar S., Khan S., Bilal A., Manzoor S., Abdullah M., Emwas A.-H., Sioud S., Gao X., Chotana G.A., Faisal A., Saleem R.S.Z. | 2017 |
| Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization Approach | Journal of Medicinal Chemistry | Innocenti P., Woodward H.L., Solanki S., Naud S., Westwood I.M., Cronin N., Hayes A., Roberts J., Henley A.T., Baker R., Faisal A., Mak G.W.-Y., Box G., Valenti M., De Haven Brandon A., O'Fee L., Saville H., Schmitt J., Matijssen B., Burke R., Van Montfort R.L.M., Raynaud F.I., Eccles S.A., Linardopoulos S., Blagg J., Hoelder S. | 2016 |
| 7-(Pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine-based derivatives for kinase inhibition: Co-crystallisation studies with Aurora-A reveal distinct differences in the orientation of the pyrazole N1-substituent | Bioorganic and Medicinal Chemistry Letters | Bavetsias V., Perez-Fuertes Y., McIntyre P.J., Atrash B., Kosmopoulou M., O'Fee L., Burke R., Sun C., Faisal A., Bush K., Avery S., Henley A., Raynaud F.I., Linardopoulos S., Bayliss R., Blagg J. | 2015 |
| Naturally occurring mutations in the MPS1 gene predispose cells to kinase inhibitor drug resistance | Cancer Research | Gurden M.D., Westwood I.M., Faisal A., Naud S., Cheung K.-M.J., McAndrew C., Wood A., Schmitt J., Boxall K., Mak G., Workman P., Burke R., Hoelder S., Blagg J., Van Montfort R.L.M., Linardopoulos S. | 2015 |
| Targeting the PPM1D phenotype; 2,4-bisarylthiazoles cause highly selective apoptosis in PPM1D amplified cell-lines | Bioorganic and Medicinal Chemistry Letters | Cheeseman M.D., Faisal A., Rayter S., Barbeau O.R., Kalusa A., Westlake M., Burke R., Swan M., Van Montfort R., Linardopoulos S., Jones K. | 2014 |
| Structure-based design of orally bioavailable 1 h -Pyrrolo[3,2- C ]pyridine inhibitors of mitotic kinase monopolar spindle 1 (MPS1) | Journal of Medicinal Chemistry | Naud S., Westwood I.M., Faisal A., Sheldrake P., Bavetsias V., Atrash B., Cheung K.-M.J., Liu M., Hayes A., Schmitt J., Wood A., Choi V., Boxall K., Mak G., Gurden M., Valenti M., De Haven Brandon A., Henley A., Baker R., McAndrew C., Matijssen B., Burke R., Hoelder S., Eccles S.A., Raynaud F.I., Linardopoulos S., Van Montfort R.L.M., Blagg J. | 2013 |
| Aurora isoform selectivity: Design and synthesis of imidazo[4,5- B ]pyridine derivatives as highly selective inhibitors of aurora-A kinase in cells | Journal of Medicinal Chemistry | Bavetsias V., Faisal A., Crumpler S., Brown N., Kosmopoulou M., Joshi A., Atrash B., Perez-Fuertes Y., Schmitt J.A., Boxall K.J., Burke R., Sun C., Avery S., Bush K., Henley A., Raynaud F.I., Workman P., Bayliss R., Linardopoulos S., Blagg J. | 2013 |
| Optimization of imidazo[4,5- b ]pyridine-based kinase inhibitors: Identification of a dual FLT3/aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia | Journal of Medicinal Chemistry | Bavetsias V., Crumpler S., Sun C., Avery S., Atrash B., Faisal A., Moore A.S., Kosmopoulou M., Brown N., Sheldrake P.W., Bush K., Henley A., Box G., Valenti M., De Haven Brandon A., Raynaud F.I., Workman P., Eccles S.A., Bayliss R., Linardopoulos S., Blagg J. | 2012 |
| Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: A model for emerging clinical resistance patterns | Leukemia | Moore A.S., Faisal A., De Castro D.G., Bavetsias V., Sun C., Atrash B., Valenti M., De Haven Brandon A., Avery S., Mair D., Mirabella F., Swansbury J., Pearson A.D.J., Workman P., Blagg J., Raynaud F.I., Eccles S.A., Linardopoulos S. | 2012 |
| The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in Vivo | Molecular Cancer Therapeutics | Faisal A., Vaughan L., Bavetsias V., Sun C., Atrash B., Avery S., Jamin Y., Robinson S.P., Workman P., Blagg J., Raynaud F.I., Eccles S.A., Chesler L., Linardopoulos S. | 2011 |
| Cisplatin induces apoptosis through the ERK-p66shc pathway in renal proximal tubule cells | Cancer Letters | Clark J.S., Faisal A., Baliga R., Nagamine Y., Arany I. | 2010 |
| Structure-based design of imidazo[1,2-a]pyrazine derivatives as selective inhibitors of Aurora-A kinase in cells | Bioorganic and Medicinal Chemistry Letters | Bouloc N., Large J.M., Kosmopoulou M., Sun C., Faisal A., Matteucci M., Reynisson J., Brown N., Atrash B., Blagg J., McDonald E., Linardopoulos S., Bayliss R., Bavetsias V. | 2010 |
| Imidazo[4,5-b]pyridine derivatives as inhibitors of aurora kinases: Lead optimization studies toward the identification of an orally bioavailable preclinical development candidate | Journal of Medicinal Chemistry | Bavetsias V., Large J.M., Sun C., Bouloc N., Kosmopoulou M., Matteucci M., Wilsher N.E., Martins V., Reynisson J., Atrash B., Faisal A., Urban F., Valenti M., De Haven Brandon A., Box G., Raynaud F.I., Workman P., Eccles S.A., Bayliss R., Blagg J., Linardopoulos S., McDonald E. | 2010 |
| p66SHC-mediated mitochondrial dysfunction in renal proximal tubule cells during oxidative injury | American Journal of Physiology - Renal Physiology | Arany I., Faisal A., Clark J.S., Vera T., Baliga R., Nagamine Y. | 2010 |
| A cancer-associated Aurora a mutant is mislocalized and misregulated due to loss of interaction with TPX2 | Journal of Biological Chemistry | Bibby R.A., Tang C., Faisal A., Drosopoulos K., Lubbe S., Houlston R., Bayliss R., Linardopoulos S. | 2009 |
| The regulated assembly of a PKCe complex controls the completion of cytokinesis | Nature Cell Biology | Saurin A.T., Durgan J., Cameron A.J., Faisal A., Marber M.S., Parker P.J. | 2008 |